Folic acid with standard immunotherapy for liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding folic acid to the usual first-line treatment (two drugs called atezolizumab and bevacizumab) is safe and works better for people with advanced liver cancer that cannot be surgically removed. It may help your body fight the cancer while controlling bleeding risks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with liver cancer (hepatocellular carcinoma) that cannot be surgically removed.
- You have not received any previous whole-body (systemic) treatment for your liver cancer.
- Your cancer is measurable on a scan and you are generally well enough to care for yourself (ECOG 0 or 1).
- Your liver function is good (Child-Pugh class A) and your blood counts and kidney function are within the required limits.
- You have not had major bleeding, uncontrolled blood pressure, or certain other serious conditions in the past 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new combination therapy for liver cancer that cannot be surgically removed. It uses an immune-boosting drug (atezolizumab), a drug that blocks blood flow to tumors (bevacizumab), and a type of chemotherapy that is delivered directly into the liver artery (HAIC). This combination may help shrink liver tumors and improve outcomes.
This trial tests a new combination of chemotherapy (FOLFOX) plus atezolizumab and bevacizumab for people with advanced liver cancer that has grown after having atezolizumab and bevacizumab alone. The goal is to see if adding chemo helps stop the cancer from growing further.
This trial tests if combining two immunotherapy drugs (atezolizumab and bevacizumab) with a brain-health medicine (memantine) can help people with advanced liver cancer that isn't treatable with surgery. It aims to see if this triple therapy works better than standard options.
This trial tests a combination of two medications, bevacizumab and atezolizumab, given one after the other to treat advanced liver cancer that cannot be surgically removed. It is specifically for people whose liver cancer is linked to a fatty liver condition (MASLD). The goal is to see if this approach helps shrink tumors or control the disease.
This trial tests a combination of an immunotherapy drug (adebrelimab) and a targeted therapy (bevacizumab) given through a vein or directly into the liver artery, along with standard chemotherapy directly into the liver artery, for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this approach can shrink or control the cancer.
This trial tests a new combination treatment for liver cancer that cannot be removed with surgery. It combines targeted therapy and immunotherapy with a procedure that delivers chemotherapy directly to the liver, aiming to shrink tumors and improve outcomes.
Hear when a new Unresectable Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.